0% found this document useful (0 votes)
20 views31 pages

Understanding Regulatory Affairs in Pharma

Uploaded by

Uma Maheshwari
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
20 views31 pages

Understanding Regulatory Affairs in Pharma

Uploaded by

Uma Maheshwari
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

KYI/Draft 01/29/08/2025

[Link]

1
KYI/Draft 01/29/08/2025
[Link]

2
[Link]
KYI/Draft 01/29/08/2025

Module 1 : What is Regulatory Affairs

3
[Link]

Module 1: What is Regulatory Affairs

It is a unique mix of science and management to achieve a


KYI/Draft 01/29/08/2025

commercially important goal within a drug development organization.

It includes everything relating to drugs from the earliest nonclinical


studies, through development, into routine manufacture and marketing,
can add significant impact for patients and drug companies.
4
[Link]

Regulatory Affairs (Department)


KYI/Draft 01/29/08/2025

Healthcare Industries

Pharmaceuticals, Medical Devices,


Biologics and Functional Foods
5
[Link]

Major multinational pharmaceutical


corporations or small, innovative
biotechnology companies
KYI/Draft 01/29/08/2025

Regulatory Affairs Department

6
[Link]

Historical Overview
During 1950s, multiple tragedies i.e. sulfanilamide elixir,
vaccine tragedy and thalidomide tragedy have resulted in
KYI/Draft 01/29/08/2025

substantial increase of legislations for drug products quality,


safety and efficacy.

This has also resulted into stricter norms for Marketing


Authorization (MA) and Good Manufacturing Practices
(GMPs).

7
[Link]

Historical Overview of Regulatory Affairs (Key regulatory events with year)


KYI/Draft 01/29/08/2025

8
[Link]

All medicines must meet 3 criteria :


KYI/Draft 01/29/08/2025

Quality Efficacy

Safety

9
[Link]

Pharmaceutical Drug Regulatory Affairs (DRA)


is a dynamic field that includes following aspects
of drug development:
KYI/Draft 01/29/08/2025

Scientific

Legal

Commercial
10
[Link]

Drug development to commercialization is highly regulated.


Every drug before getting market approval must undergo
KYI/Draft 01/29/08/2025

rigorous scrutiny and clinical trials to ensure its safety, efficacy


and quality.
These standards are set by regulatory authorities of their
respective countries such as FDA in US and CDSCO in India
etc.
11
[Link]

Regulation of Drug products involve following areas –


Non-clinical and Clinical Drug Development Guidelines
Licensing (Patent)
KYI/Draft 01/29/08/2025

Drug Registration
Manufacturing
Quality and safety Guidance
Pricing and Trademark
Marketing, Import and Distribution of Drug products
Pharmacovigilance (Adverse Drug Reactions monitoring)
12
KYI/Draft 01/29/08/2025
[Link]

13
[Link]

Major regulatory agencies


World Health Organization (WHO),
United States Food and Drug Administration (USFDA, United States),
European Medicines Agency (EMA, European Union),
KYI/Draft 01/29/08/2025

Medicines and Healthcare Products Regulatory Agency (MHRA, UK),


Therapeutic Goods Administration (TGA, Australia),
Health Canada (Canada),
Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
Agency Nacional degradation vigilancia sonotoria (ANVISA, Brazil)
Medicine control council (MCC, South Africa)
Central Drugs Standard Control Organization (CDSCO, India).
14
[Link]

IMPORTANCE OF REGULATORY AFFAIRS

In today's competitive environment the reduction of the


KYI/Draft 01/29/08/2025

time taken to reach the market is critical to a product's and


hence the company's success.

The proper conduct of its Regulatory Affairs activities is


therefore of considerable economic importance for the
company.

15
[Link]

Not unified across the


companies and is
Organizational changing
KYI/Draft 01/29/08/2025

Structure of • Global Regulatory Affairs


Regulatory • Regional Regulatory Affairs
Affairs • Local Regulatory Affairs
• Manufacturing Site Regulatory
Affairs
• Drug Agency Regulatory
Affairs
16
KYI/Draft 01/29/08/2025
[Link]

17
[Link]
KYI/Draft 01/29/08/2025

Module 2
The role of Regulatory Affairs department

18
[Link]

Regulatory affairs professionals are


employed in industry, government
regulatory authorities and
REGULATORY academics. The wide range of
KYI/Draft 01/29/08/2025

regulatory professionals includes in


AFFAIRS these areas:
PROFESSIONAL
• Pharmaceuticals
IN INDUSTRIES • Medical devices
• In vitro diagnostics
• Biologics and biotechnology
• Nutritional Products
• Cosmetics

19
[Link]

Approval Phase
KYI/Draft 01/29/08/2025

Development Post Approval


Phase Phase

Role of
Drug
Regulatory
Affairs
Department

20
[Link]

Role of Drug Regulatory Affairs Department


A. Development Phase
Ensuring that the legislative requirements are met –
KYI/Draft 01/29/08/2025

- Advice on development studies to demonstrate safety, quality and efficacy parameters.


- Set up regulatory strategy.
- Participate in cross-functional project teams.
- Ensure application of guidelines for clinical trials.
- Submission of application to conduct clinical trials.
- Managing the regulatory submission -
- Minimize time to market (everyday counts!)
- Advice on a global development plan

21
[Link]

Optimize submission strategies -

– Dossier preparation
KYI/Draft 01/29/08/2025

– Format, document re-use

– Electronic submissions

– Review high-level documents/reports

Interact with commercial side of business such as pricing and reimbursement.

22
[Link]

Regulation of drug approval process


KYI/Draft 01/29/08/2025

23
[Link]

B. Approval Phase

Clarify raised questions,


Check progress of
KYI/Draft 01/29/08/2025

plan response and


evaluation and anticipate
strategies with other
questions.
departments.

Negotiate approval and


Plan and manage agency
Product Information with
meetings/hearings.
agencies.

24
[Link]

1. Discovery/
development
Team
2. Nonclinical
7. pharmacology
and toxicology
Management Team/ 3.
Team Clinical
KYI/Draft 01/29/08/2025

research Team
Regulatory
requirements
for drug
approval
4. Regulatory
6. Legal Team
affairs Team

5. Marketing
Team

25
[Link]

C. Post approval Phase

Compliance
Submission of variations/amendments
KYI/Draft 01/29/08/2025

Renewals
Pharmacovigilance
Product information review
New indications / new formulations
Regulatory input to development plans/ Regulatory Intelligence.
26
KYI/Draft 01/29/08/2025
[Link]

27
[Link]

Responsibility of the Regulatory Affairs Professionals –

 Ensuring that their companies comply with all the regulations and laws
 Working with federal, state and local regulatory agencies and personnel
KYI/Draft 01/29/08/2025

 Advising companies on the regulatory aspects


 Keep in touch with international legislation, guidelines and customer practices
 Keep up to the date with a company’s product range
 Collect, collate, and evaluate the scientific data that their research and development
 Formulate regulatory strategies for all appropriate regulatory submissions such as domestic,
international and/or contract projects
 Coordinate, prepare and review all appropriate documents for example dossier and submit them to
regulatory authorities
28
[Link]

Prepare and review Prepare and review of SOPs

Review Review of BMR, MFR, change control and other relevant documents.

Monitor Monitor the progress of all registration submission


KYI/Draft 01/29/08/2025

Maintain Maintain approved applications and the record of registration fees paid

Respond Respond to queries and ensure that registration/ approval are granted

Participate in R&D training, Pilot plant Scale Up, and Post Marketing Surveillance
Participate in (ADR)
Manage and review audit reports and compliance, regulatory and customer
Manage and review inspections
Provide accurate and complete information about the quality, safety and
Provide effectiveness of the product to the physicians and other healthcare professionals.

29
KYI/Draft 01/29/08/2025
[Link]

30
KYI/Draft 01/29/08/2025
[Link]

31

You might also like